- Home
- ANGX vs MNPR Comparison
ANGX vs MNPR Comparison
Compare ANGX & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGX | MNPR |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | 311 | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 546.0M | 587.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ANGX | MNPR |
|---|---|---|
| Price | $3.54 | $97.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $9.75 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 1.2M | 144.8K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $46.23 | N/A |
| Revenue Next Year | $25.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.05 | $29.18 |
| 52 Week High | $18.90 | $105.00 |
Technical Indicators
Market Signals| Indicator | ANGX | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 62.13 | 83.34 |
| Support Level | $3.03 | $52.92 |
| Resistance Level | $3.97 | $103.17 |
| Average True Range (ATR) | 0.25 | 6.06 |
| MACD | 0.05 | 2.84 |
| Stochastic Oscillator | 79.82 | 93.86 |
Price Performance
Historical ComparisonAbout ANGX Angel Studios Inc.
Angel Studios Inc is an entertainment company known for crowd-funded films and television projects. It enables creators to share projects and engage audiences directly. The platform allows fans to invest in and promote productions, fostering a community-driven approach to content creation.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.